Sylvia Musto
Overview
Explore the profile of Sylvia Musto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
462
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhou D, Casavant J, Graziani E, He H, Janso J, Loganzo F, et al.
Bioorg Med Chem Lett
. 2019 Jan;
29(7):943-947.
PMID: 30655215
Novel neolymphostin-based antibody-drug conjugate (ADC) precursors were synthesized either through amide couplings between both cleavable and non-cleavable linkers and neolymphostin derivatives, or through Cu(I)-catalyzed acetylene-azide click cycloadditon between non-cleavable linkers...
2.
Ratnayake A, Chang L, Tumey L, Loganzo F, Chemler J, Wagenaar M, et al.
Bioconjug Chem
. 2018 Dec;
30(1):200-209.
PMID: 30543418
A potent class of DNA-damaging agents, natural product bis-intercalator depsipeptides (NPBIDs), was evaluated as ultrapotent payloads for use in antibody-drug conjugates (ADCs). Detailed investigation of potency (both in cells and...
3.
Shah D, Loganzo F, Haddish-Berhane N, Musto S, Wald H, Barletta F, et al.
J Pharmacokinet Pharmacodyn
. 2018 Feb;
45(2):339-349.
PMID: 29423862
The objective of this manuscript was to establish in vitro-in vivo correlation (IVIVC) between the in vitro efficacy and in vivo efficacy of antibody drug conjugates (ADCs), using a PK/PD...
4.
Puthenveetil S, He H, Loganzo F, Musto S, Teske J, Green M, et al.
PLoS One
. 2017 May;
12(5):e0178452.
PMID: 28558059
Antibody drug conjugates (ADCs) are no longer an unknown entity in the field of cancer therapy with the success of marketed ADCs like ADCETRIS and KADCYLA and numerous others advancing...
5.
Tumey L, Li F, Rago B, Han X, Loganzo F, Musto S, et al.
AAPS J
. 2017 Apr;
19(4):1123-1135.
PMID: 28439809
As the antibody drug conjugate (ADC) community continues to shift towards site-specific conjugation technology, there is a growing need to understand how the site of conjugation impacts the biophysical and...
6.
Kulkarni C, Finley J, Bessire A, Zhong X, Musto S, Graziani E
Bioconjug Chem
. 2017 Feb;
28(4):1041-1047.
PMID: 28191936
As the antibody-drug conjugate (ADC) field grows increasingly important for cancer treatment, it is vital for researchers to establish a firm understanding of how ADCs function at the molecular level....
7.
Leverett C, Sukuru S, Vetelino B, Musto S, Parris K, Pandit J, et al.
ACS Med Chem Lett
. 2016 Nov;
7(11):999-1004.
PMID: 27882198
The tubulysin class of natural products has attracted much attention from the medicinal chemistry community due to its potent cytotoxicity against a wide range of human cancer cell lines, including...
8.
Tumey L, Leverett C, Vetelino B, Li F, Rago B, Han X, et al.
ACS Med Chem Lett
. 2016 Nov;
7(11):977-982.
PMID: 27882194
As part of our efforts to develop new classes of tubulin inhibitor payloads for antibody-drug conjugate (ADC) programs, we developed a tubulysin ADC that demonstrated excellent in vitro activity but...
9.
Puthenveetil S, Loganzo F, He H, Dirico K, Green M, Teske J, et al.
Bioconjug Chem
. 2016 Jul;
27(8):1880-8.
PMID: 27412791
There is a considerable ongoing work to identify new cytotoxic payloads that are appropriate for antibody-based delivery, acting via mechanisms beyond DNA damage and microtubule disruption, highlighting their importance to...
10.
Puthenveetil S, Musto S, Loganzo F, Tumey L, ODonnell C, Graziani E
Bioconjug Chem
. 2016 Mar;
27(4):1030-9.
PMID: 26942771
The focus of the antibody-drug conjugate (ADC) field is shifting toward development of site-specific, next-generation ADCs to address the issue of heterogeneity, metabolic instability, conjugatability, and less than ideal therapeutic...